pirfenidone has been researched along with Coronary Artery Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chou, W; Glassberg, MK; Lin, CY; Morgenthien, EA; Nathan, SD; Noble, PW; Stauffer, JL | 1 |
| Margaritopoulos, G | 1 |
1 trial(s) available for pirfenidone and Coronary Artery Disease
| Article | Year |
|---|---|
Cardiovascular Risks, Bleeding Risks, and Clinical Events from 3 Phase III Trials of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Cardiovascular Agents; Cardiovascular Diseases; Coronary Artery Disease; Female; Hemorrhage; Humans; Idiopathic Pulmonary Fibrosis; Male; Middle Aged; Pyridones; Retrospective Studies; Risk Factors; Treatment Outcome; Warfarin | 2019 |
1 other study(ies) available for pirfenidone and Coronary Artery Disease
| Article | Year |
|---|---|
Challenges in IPF diagnosis, current management and future perspectives: Patient case 2.
Topics: Adrenal Cortex Hormones; Aged; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Eruptions; Follow-Up Studies; Hemoptysis; Humans; Hypertension; Idiopathic Pulmonary Fibrosis; Male; Pyridones; Risk Assessment; Severity of Illness Index; Tachycardia, Supraventricular; Tomography, X-Ray Computed; Treatment Outcome | 2015 |